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The Effects of Human New Pressor Protein and 
Coagulation Factor XIIa on Blood Pressure and 
Heart Rate in Bilaterally Nephrectomized Rats 
 
 
 
Abstract 
Background: New Pressor Protein (NPP) is a human plasma 
enzyme structurally related to b–fragment of activated factor 
XІІ (β-FXIIa). The objective of the present study was to inves-
tigate the effects of NPP and β-FXIIa on systolic blood pressure 
and heart rate in bilateral nephrectomized rats. 
 
Methods: Forty male Wistar rats (250-300 g) were sham-
operated or bilaterally nephrectomized under anesthesia with a 
combination of halothane, nitrous oxide and oxygen. Twenty 
four hours later under anesthesia with Inactin (100 mg/kg), 
they were ganglion blocked (pentolinium tartrate; 19.2 
mg/kg), and their systolic blood pressure and heart rate were 
measured before and after intravenous administration of cap-
topril (2.5 mg/kg), NPP (20μl plasma equivalent) or purified 
β-FXIIa (300 ng/kg). 
 
Results: NPP raised the systolic blood pressure by 31±2 
mmHg and heart rate by 19±2 bpm in sham-operated rats. 
Captopril caused systolic blood pressure and heart rate to in-
crease significantly by 64±7 mmHg and 107±9 bpm, respec-
tively in response to NPP. In bilateral nephrectomized rats, 
NPP raised systolic blood pressure by 57±6 mmHg and heart 
rate by 70±13 bpm in the absence of captopril, which were not 
significantly different from those (46±3 mmHg and 75±8 
beats/min) in the presence of captopril. 
 
Conclusion: This study shows that the effects of NPP and β-
fragment of factor XІІ on systolic blood pressure and heart 
rate are similar, suggestive of a functional relationship be-
tween them. The findings might suggest that the potentiation 
effect of captopril in sham-operated or bilaterally nephrec-
tomized rats is primarily expressed via renal enzymes. 
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Introduction 
ew Pressor Protein (NPP) is an extrarenal enzyme de-
rived from trypsin-activated normal human and rat plas-
mas. Biochemical studies of human NPP revealed that it 
was a heat labile enzymatic protein with a molecular mass of ~30 
KDa and an isoelectric point of 4.7 to 4.9. Its amino-terminal se-
quences (19 amino acid residues) indicated strong homology 
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with the heavy chain of the β-fragment of acti-
vated human coagulation factor XII (β-FXIIa).1,2 
Structural and functional properties of NPP 
indicate that its effects can not be attributed to 
any identifiable pressor agent including angio-
tensin II or endothelin. 
Intravenous physiological bolus doses (10-
20μl plasma equivalent /~300g) of impure hu-
man or rat NPP in rats produced biphasic or 
multiphasic blood pressure responses. They 
were associated with a small and brief initial 
depressor phase followed by a much more 
prominent and prolonged (10-15 min) pressor 
phase accompanied by a marked elevation in 
heart rate (HR).3 
In a series of preliminary experiment, we 
found that bilateral nephrectomy (2NX) poten-
tiated NPP responses. Hypertension is a 
common problem among pediatric hemodialy-
sis patients.4 The present study aimed at de-
termining further the mechanism of action of 
NPP and the role of kidneys on its responses. 
 
Methods 
 
Statement of ethical guidelines 
Animal used in the present study were 
cared for and used in accordance with the 
principles and guidelines outlined by the Ca-
nadian Council on Animal Care. All experimen-
tal protocols were approved by the relevant 
Animal Care Committees of the Faculty of 
Medicine and the University of Toronto. 
 
Surgery and instrumentation  
Male Wistar rats (n=40) weighing 250-300 g 
were obtained form Canadian Biobreeding 
Laboratories. Animals were subjected to sham-
operation or nephrectomy as described previ-
ously.5 Briefly, under anesthesia by a mixture 
of halothane and nitrous oxide in pure oxygen 
the hairs of animals backed at the level of last 
rib and the flank areas were shaved, and the 
shaved areas were antisepticised with a 70% 
ethanol. A mid-line skin incision was made 
above the spinal cord. Through the incision, 
the skin around it was separated laterally by 
blunt dissection. Afterwards, the incision was 
pulled to the right and left. An incision was 
made in the muscular layers of the flank areas, 
and the kidneys were exposed. The adrenal 
vessels were tied with a 1-0 silk thread tempo-
rarily, and the kidneys were decapsulated to 
preserve the adrenal gland and removed. The 
sham-operated rats were subjected to a similar 
operation, but kidneys were not removed. The 
muscular incision was sutured with a 3-0 silk 
thread, and the mid-line skin incision was 
closed with a 9 mm stainless steel autoclip. 
The animals were allowed to recover from  
anesthesia, and kept in cages with free access 
to water and rodent chow. 
Twenty four hours later, animals were anes-
thetized with Inactin (100mg/kg), and right ca-
rotid arteries were cannulated using PE-50 
polyethylene catheters for arterial systolic 
blood pressure (SBP) and HR recordings, us-
ing Statham DC pressure transducers (Hato 
Rey). The transducers were connected to a 
MacLab/8 data acquisition system (AD Instru-
ments and Lamont Scientific, Toronto, Can-
ada) connected to a Power Macintosh 
7200/1200 PC compatible computer and driven 
by MacLab Chart Version 3.5.6 software. Only 
rats that had sustained minimal tissue trauma 
and blood loss, and had stable BP (~80/40 
mmHg, systolic/diastolic blood pressure) and 
HR (~350 beats/min) were used for the ex-
periments, otherwise excluded. All the animals 
received single subcutaneous injections of 
ganglion-blocking agent pentolinium tartrate 
(19.2 mg/kg) and atropine sulphate (2.4 mg/kg) 
during surgery. 
 
Experiments design and protocol 
The rats were assigned to two series. The 
first series were 2NX rats including two groups 
(n=8-10 each) receiving captopril or vehicle. 
The second series were sham-operated rats 
divided into 2 groups (n=8-10 each) in a similar 
manner as 2NX rats. Captopril (2.5 mg/kg) was 
administered intravenously 40 min before the 
SBP and HR recordings. Animals in each 
group received single intravenous injections of 
NPP (20 µl plasma equivalent) and β-FXIIa 
(300 ng/kg), SBP, or HR increment was calcu-
lated at the peak of blood pressure responses. 
 
Human plasma and preparation of NPP 
Human plasmas that were considered nor-
mal but unsuitable for transfusion purposes, 
were obtained from the Canadian Services 
(formerly the Canadian Red Cross Society To-
ronto Center, ON, Canada). The plasma bags 
were thawed in cold tap water, and aliquots 
were used immediately or frozen at -20°C in 
capped polystyrene tubes for later use.1 
Plasma was activated with trypsin in a con-
trolled reaction, as described previously.1,3 
Briefly, trypsin (type ІІІ, bovine, T-8253; Sigma 
Chemical Co., St Louis, Missouri, USA) was 
prepared as a stock solution in 0.002 mol/l HCl 
and added to plasma, with mixing at 3-10% v/v 
to achieve a final trypsin concentration of 1 
mg/ml ensuring minimal plasma dilution. After 
incubation for 10 min at 23°C, the reaction was 
terminated by rapid freezing on dry ice. The 
activated plasma preparation was administered 
to rats at a dose of 20 μl/300g rat, expressed 
in terms of plasma equivalence. The pressor 
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properties of this preparation were shown to be 
virtually interchangeable with our own highly 
purified preparations of NPP,3 or with a com-
mercially obtained highly purified β-FXІІa 
fragment.1 
 
Drugs 
The ganglion-blocking agent pentolinium 
tartrate salt (P-3520, Sigma-Aldrich, Poulenc, 
Montreal, Canada) was dissolved in poly vinyl 
pyrrolidine for continuous release during the 
experiment. Inactin (Promonta, Hamburg, 
Germany) and captopril (Sigma-Aldrich C-
4042, St Louis, Mo, USA) were dissolved in 
0.9% saline. Atropine sulphate was obtained 
from Ingram and Bell (Toronto, ON, Canada). 
Human coagulation b-FXIIa was obtained from 
Enzyme Research Laboratories (South Bend, 
IN, US). Aliquots of b-FXIIa were prepared in 
concentrations of 10 ng/µl, and were stored at 
-40°C. The aliquots were kept on ice during the 
experiments. 
 
Statistical analysis 
Results are expressed as Mean ± SEM. 
Statistical comparisons were made using 
either one-way analysis of variance, followed 
by Duncan's Multiple Range test, or paired or 
unpaired Student t test where appropriate.  
A P≤0.05 was considered statistically  
significant. 
Results 
 
The effects of intravenous injections of human 
NPP and purified human β-FXІIa in sham-
operated rats 
The injections of physiological saline or 
normal human inactivated plasma did not 
change the SBP and HR in rats pretreated with 
captopril (fig1-A). However, NPP and purified 
human coagulation β-FXIIa produced a bi-
phasic effects on SBP comprising of an initial 
small decrease followed by a much larger in-
crease accompanied by an increase in HR 
lasting for approximately 15 min (fig1 B, C). 
 
The effect of captopril pretreatment on SBP and 
HR responses to NPP and β-FXIIa in sham-
operated rats  
The administration of NPP and β-FXIIa to 
sham-operated rats caused increases in SBP of 
31.7±2.0 and 17.6±2.0 mmHg, respectively. 
They also caused increases in HR 19.8±2.0 and 
13.6±2.0 bpm, respectively. The administration of 
NPP and β-FXIIa after pretreatment with capto-
pril increased SBP 64.2±7.0 and 56±4.0 mmHg, 
respectively. Also they caused increases in HR 
108±9 and 92±10 bpm, respectively. The in-
creases in SBP and HR caused by both com-
pounds in the presence of captopril were signifi-
cantly higher than the respective values in the 
absence of pretreatment with captopril (fig 2). 
  
Fig 1: Representative systolic blood pressure (SBP, mmHg) and heart rate (HR, beats per minute, bpm) responses to physio-
logical saline, normal inactivated human plasma (A), to human NPP (20µl plasma activated equivalent i.v.) (B) and coagulation 
β-FXIIa (300 ng/kg) (C). Human NPP and highly purified β -FXIIa produced comparable SBP and HR responses in bioassay 
rats lasting ~15 min. Physiological saline or normal (control) human plasma preparation not activated with trypsin produced no 
change in these responses.  
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Fig 2: Effect of human NPP (20µl plasma activated 
equivalent, i.v.) or β-FXIIa (300 ng/kg, i.v) on systolic 
blood pressure (SBP, mmHg) (A) and on heart rate (HR, 
bpm) (B) in sham-operated rats. Open bars show re-
sponses before captopril and dark bars show responses 
after captopril (CAP, 2.5 mg/kg, i.v.) injection. There are 
significant differences between these groups before and 
after captopril treatment. ٭٭P<0.01, ٭٭٭P<0.001. (Mean 
± SEM, n=8-10). 
 
 
 
The effect of captopril pretreatment on SBP 
and HR responses to NPP and β-FXIIa in 2NX 
rats  
The administration of NPP or β-FXIIa to 
nephrectomized rats evoked marked in-
creases in SBP 57.7±6.0 and 42.9±4.0 
mmHg, respectively. They also caused in-
creases in HR 70.4±13 and 51.7±14 bpm, 
respectively. The responses started with a 
brief decrease, followed by a quick increase 
in SBP and DBP. After the quick rise, pres-
sure began to fall and reached to baseline 
within 15 minutes. The administration of NPP 
and β-FXIIa after pretreatment with captopril 
caused increases in SBP 46.7±3.0 and 
43.9±6.0 mmHg and increases in HR 
75.1±8.0 and 85.0±12.0 bpm, respectively 
(fig 3). These values were not significantly 
different from identical values in the absence 
of captopril. 
 
 
 
Fig 3: Effect of human NPP (20µl plasma activated 
equivalent, i.v.) or β-FXIIa (300 ng/kg, i.v.) on systolic 
blood pressure (SBP, mmHg) (A) and on heart rate 
(HR,bpm) (B) in 24 hr nephrectomized (2NX) rats. Open 
bars show responses before captopril and dark bars 
show responses after captopril (CAP, 2.5 mg/kg, i.v.) 
injection. There are no significant differences between 
these groups before and after captopril treatment. (Mean 
± SEM, n=8-10). 
 
 
 
Discussion 
 
The findings of the present study indicate that 
the administration of captopril in sham-operated 
rats as well as nephrectomy potentiated the 
increase in SBP and HR evoked by NPP and β-
FXIIa. It also showed that captopril failed to po-
tentiate such responses in 2NX rats (fig 3). 
Trypsin-activated normal human plasma 
produced a characteristic pressor SBP and HR 
responses (fig 1-B). In contrast, untrypsinized 
human plasma or saline solution exhibited no 
responses (fig 1-A). NPP is homologous to β-
FXIIa, which has similar pressor and chrono-
tropic characteristic (fig1-C). Structural and 
enzymic studies confirm the relationship be-
tween NPP and β-FXIIa.1-3 
Since trypsin can activate pro-renin to 
renin, which produces pressor effects in 2NX 
rats,3 it is expected that renin angiotensin system 
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might be involved. However, the present study 
showed that pretreatment with captopril in 
ganglion–blocked sham-operated rats not only 
could prevent pressor or HR responses but 
also potentiated such effects (fig 2-A, B). Simi-
lar effects were also reported with enalapril 
suggesting that ACE inhibition could potentiate 
NPP effects.1,3 Moreover, it was reported that 
peptides such as bradykinin and pituitary ade-
nylate cyclase activating polypeptide (PACAP) 
might mediate NPP responses.6,7 Therefore, it 
is likely that captopril did potentiate the re-
sponses to NPP and β-FXIIa via the preserva-
tion of these peptides (fig 2-A, B). Since capto-
pril pretreatment could not lower BP response 
to NPP, renin angiotensin system might not be 
involved in NPP pressor effects. 
Hypertension is prevalent among pediatric 
hemodialysis patients.4 The role of NPP in hy-
pertensive hemodialysis patients is not known. 
In a previous study we showed that plasma 
levels of NPP and β-FXIIa were high in hemo-
dialysis patients.8 The present study used 24 
hrs 2NX rats to investigate the role of NPP and 
the role of ACE inhibition in NPP effects. The 
2NX rats were chosen, since the removal of 
renal ACE was expected to simulate the poten-
tiating effects of captopril. The findings suggest 
that the effects of NPP and b-FXIIa on SBP, 
HR, and the potentiation of their effects by cap-
topril were quite similar in sham-operated rats 
(fig 2-A, B). However, 2NX alone produced 
virtually the same potentiation of responses to 
NPP and b-FXIIa as did captopril in sham-
operated rats (fig 3-A, B). This finding might 
suggest that the effects of captopril were pri-
marily expressed via renal peptidases. Since 
tissues other than kidney have ACE, captopril 
was not able to increase more the effects of 
NPP and β-FXIIa in 2NX rats. This suggests 
that the potentiating effect of 2NX on SBP and 
HR responses might be due to the removal of 
other renal peptidases such as neutral 
endopeptidase (NEP).9 Thus, it is a non-
clearance mechanism and is due to the pres-
ervation of peptides, which mediate cate-
cholamine release. These peptides are sensi-
tive to biodegrading by ACE and NEP.10 
Another possibility for the potentiating ef-
fect of 2NX might be the elevation of extrare-
nal pro-renin and angiotensinogen levels.11,12 
NPP or β-FXIIa might produce a significant 
amount of angiotensinII by converting pro-
renin to renin in such a model. Angiotensin II 
increases BP and thus potentiates NPP re-
sponses. However, pretreatment of 2NX rats 
with Losartan, an AT-1 receptor antagonist, 
did not change NPP pressor effects,7 there-
fore, the role of RAS in NPP response re-
mains equivocal. 
The fact that captopril potentiated HR re-
sponses more than SBP ones to NPP in sham-
operated rats (444% vs 102%) suggests that 
the mechanisms governing HR are not entirely 
similar to those governing SBP. Overall, the 
findings of the present study and those from 
previous ones,1-3,13 solidify the relationship be-
tween NPP and β-FXIIa, and demonstrate that 
complex mechanisms of action on SBP and 
HR are importantly mediated by the kidneys. 
In conclusion, the findings strongly support 
the similarity between NPP and β-FXIIa effects 
for elevating SBP and HR. These responses 
are potentiated in nephrectomized rats, sug-
gesting the involvement of kidneys. In patients 
with renal ablation or renal failure, this hyper-
tensive effect might exist. 
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